Cu2LCl2(H2O)
Cu2LCl2(H2O) acts as a proteasome inhibitor and protein tyrosine phosphatase inhibitor, with antiproliferative and apoptosis-inducing effects. Cu2LCl2(H2O) exhibits low cytotoxicity against normal cells and remarkable in vivo antitumor efficacy. Cu2LCl2(H2O) inhibits proteasome activity in colon cancer cells, and suppresses PTP1B and TCPTP activities in breast cancer cells. Cu2LCl2(H2O) can be used in the research of colon cancer, breast cancer and liver cancer.
For research use only. We do not sell to patients.
- Formula: C13H15Cl2Cu2N8OS
- Molecular Weight:529.37
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
[Cu2LCl2(H2O)] (compound 1) (0.5-25 μM; 48 h) potently inhibits proliferation of HCT-116, SW-480, HepG-2, and MCF-7 human tumor cells with IC50 values ranging from 0.68-1.94 μM after 48 h, while exhibiting high selectivity for colon cancer cells and moderate selectivity for liver cancer cells over normal human cells[1].
[Cu2LCl2(H2O)] (1-25 μM; 24 h) induces dose-dependent apoptosis in HCT-116 and MCF-7 human tumor cells after 24 h of treatment, with a more pronounced effect in HCT-116 cells[1].
[Cu2LCl2(H2O)] (1-10 μM; 12 h) induces dose-dependent accumulation of ubiquitinated proteins in HCT-116 and MCF-7 human tumor cells after 12 h of treatment at 1-10 μM, confirming functional proteasome inhibition[1].
[Cu2LCl2(H2O)] (1-25 μM; 12 h) modulates proteasome-related signaling pathways in HCT-116 human colon cancer cells after 12 h of treatment, increasing IκBα, p21, and Bax levels while decreasing NF-κB, Bcl-2, and E2F1 levels to induce apoptosis and cell cycle arrest[1].
[Cu2LCl2(H2O)] (1-25 μM; 12 h) inhibits PTP1B and TCPTP expression and activity in MCF-7 human breast cancer cells after 12 h of treatment, increasing phosphorylation of their downstream substrates to suppress tumor cell proliferation and induce apoptosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HCT-116, MCF-7
-
Concentration:1-25 μM
-
Incubation Time:24 h
-
Result:Increased total apoptotic cell population dose-dependently from 30.50% to 91.58% in HCT-116 cells across the concentration range.
Increased total apoptotic cell population from 11.97% to 68.88% in MCF-7 cells over the same concentration range.
-
Cell Line:HCT-116
-
Concentration:1-25 μM
-
Incubation Time:12 h
-
Result:Increased IκBα, p21, and Bax levels dose-dependently.
Decreased NF-κB, Bcl-2, and E2F1 levels dose-dependently.
Left RPN1 expression unchanged, confirming specific proteasome activity inhibition without altering core proteasome composition.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (male, 6-8 weeks old, 20-25 g, subcutaneous xenograft of human HCT-116 colon cancer cells)[1]
-
Dosage:2 mg/kg; 4 mg/kg
-
Administration:i.p.; repeated dosing; 21 days
-
Result:Achieved a tumor inhibition rate (TIR) of 59.3% at 2 mg/kg.
Achieved a tumor inhibition rate (TIR) of 88.2% at 4 mg/kg.
Showed no significant body weight loss throughout the study period.
Chemical Information
-
Molecular Weight 529.37
-
Formula C13H15Cl2Cu2N8OS
-
SMILES
CC1=[N-]2N3C([N][N]([Cu]34([OH2])Cl)=C(C5=[N]4C=CN=C5)C)S[Cu+2]2(Cl)[N-]6=C1C=NC=C6
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)